Acylated GLP-1 Analog Weekly Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Type 2 diabetes patients often experience 'needle-phobia,' making it difficult for them to administer injectable GLP-1 compounds, which are typically required daily, leading to a need for less frequent administration while maintaining clinical efficacy.
Innovation Solution
A GLP-1 analog with modifications, including a non-proteogenic amino acid residue and acylation with a moiety containing acidic groups, is developed to extend its duration of action and resistance to DPP-IV degradation, allowing for less frequent administration while maintaining receptor affinity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1 compounds are administered daily to maintain clinical efficacy, then therapeutic effect is preserved, but patient compliance deteriorates due to needle-phobia and frequent injections
Solution Approach 1:
The patent applies dynamics by transitioning from a static daily injection regimen to a dynamic extended-release formulation that gradually releases the peptide over time. The modified GLP-1 compound with lipophilic substituent and acylation creates a dynamic release profile that maintains therapeutic levels throughout the week, allowing patients to inject once weekly rather than daily, thereby improving compliance while maintaining efficacy.
Solution Approach 2:
The patent changes key parameters of the GLP-1 molecule including adding a lipophilic substituent at the C-terminal position and performing acylation at the N-terminal position. These parameter changes in molecular structure directly affect pharmacokinetic properties, extending the half-life from hours to weeks, which enables less frequent administration and improves patient compliance.
2Loss of time
If GLP-1 compounds are modified to extend duration of action, then administration frequency is reduced, but molecular complexity increases
Solution Approach 1:
The patent applies local quality by making targeted modifications at specific locations on the GLP-1 molecule rather than comprehensive restructuring. A lipophilic substituent is added locally at the C-terminal amino acid residue, and acylation is applied locally at the N-terminal position. These localized modifications extend duration of action without requiring complete redesign of the entire molecular structure, thus managing complexity.
Solution Approach 2:
The patent creates a composite molecular structure by combining the native GLP-1 peptide with external functional groups (lipophilic substituent and acylation moiety). This composite approach allows the core peptide to maintain its biological activity while the added components provide extended duration, balancing functional requirements with structural complexity.
3Duration of action of stationary object
If GLP-1 compounds are modified with lipophilic substituents and acylation to extend half-life, then duration of action increases, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the modification process into distinct, manageable steps: first introducing the lipophilic substituent at the C-terminal position, then performing acylation at the N-terminal position. This segmented approach to synthesis allows each modification to be optimized independently, making the overall manufacturing process more controllable and scalable while achieving extended duration of action.
Data Source
AI summary
Protracted GLP-1 compounds and therapeutic uses thereof.